Jeffry Pilney
New Martinsville, WVNPI 1487601647
Payments from drug & device makers
$2,159,013in general payments, 2019–2025
Across 590 payments — averaging $3659.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$613K
- Ipsen Innovation$359K
- AbbVie$347K
- Genentech, Inc.$272K
- Modernatx, Inc.$230K
- Orasure Technologies Inc.$110K
- plus $228K from 5 others
General payments by program year
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $612,915 |
| Ipsen Innovation | 327 | $359,470 |
| AbbVie | 109 | $346,594 |
| Genentech, Inc. | 30 | $271,798 |
| Modernatx, Inc. | 53 | $230,276 |
| Orasure Technologies Inc. | 5 | $110,000 |
| Chiesi USA, Inc. | 12 | $96,659 |
| Pfizer | 8 | $79,550 |
| GSK | 11 | $37,876 |
| Eli Lilly | 3 | $8,994 |
| Roche Molecular Systems, Inc. | 4 | $4,882 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.